Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, active-controlled trial to assess the efficacy
and safety of aripiprazole Intramuscular Depot in the acute treatment of adults with
schizophrenia. The trial will include a 13-day screening phase and a 12-week acute treatment
phase with a 14(±2)-day safety follow-up.